COVID-19

iCAD to Report Second Quarter 2023 Financial Results on August 14, 2023

NASHUA, N.H., July 31, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer…

12 months ago

Bionano Announces OGM Roadshow, TOUR, which Provides Education on the Company’s Workflow and Helps Build a Community of Users

SAN DIEGO, July 31, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the successful launch of its…

12 months ago

Taysha Gene Therapies Announces Positive Recommendation from Independent Data Monitoring Committee of REVEAL Phase 1/2 Trial in Rett Syndrome

Independent Data Monitoring Committee recommended REVEAL Phase 1/2 trial continuation and proceeding with dosing of second patient based on encouraging…

12 months ago

Aflibercept 8 mg Two-Year Results from Pivotal PHOTON Trial in Diabetic Macular Edema Presented at ASRS

89% and 84% of patients were maintained on ≥12- and ≥16-week dosing intervals, respectively, throughout the two-year period, while sustaining their…

12 months ago

Xtant Medical Wins Auction for Surgalign’s Hardware and Biologics Business

Acquisition to Enhance Xtant’s Growing Spinal Fusion Devices Portfolio BELGRADE, Mont., July 28, 2023 (GLOBE NEWSWIRE) -- Xtant Medical Holdings,…

12 months ago

Surgalign Successfully Completes Auction and Names Successful Bidders For Asset Sales

DEERFIELD, Ill., July 28, 2023 (GLOBE NEWSWIRE) -- Surgalign Holdings, Inc., (OTC: SRGAQ) (“Surgalign” or the “Company”), a global medical…

12 months ago

Ambrx to Present Preliminary ARX517 First-in-Human Safety, Efficacy, and Pharmacokinetics Data at ESMO 2023

Presentations represent the first time clinical data regarding ARX517 will be presented at a medical meetingSAN DIEGO, July 28, 2023…

12 months ago

Revive Therapeutics Announces Filing of Patent for Bucillamine in the Treatment of Exposure to Chemical Warfare Agents

TORONTO, July 28, 2023 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a…

12 months ago

Tonix Pharmaceuticals Announces Pricing of $7 Million Public Offering

CHATHAM, N.J., July 27, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a biopharmaceutical…

12 months ago